Press releases

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2024 Annual Report has been published

Stockholm, April 16, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m. Registration for attendees will commence at 09.30 a.m

Stockholm – April 1, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on Oncopeptides’ next-gen drug OPD5

Stockholm – March 11, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has received the first order of its flagship drug Pepaxti (melflufen) from an Italian hospital

Stockholm — 28 February, 2025 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 10,572,577 new class C shares. The shares are issued by virtue of the Annual General Meetings’ resolution on 31 May 2024 on authorisation for the Board of Directors to resolve on issue of class C shares to enable delivery of shares to participants under the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024 as well as other outstanding shareholder programs for members of the Board of Directors

Stockholm – February 27, 2025 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on difficult-to-treat cancers, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 31 May 2024, to issue and immediately thereafter re-purchase a total of 10,572,577 class C shares

Stockholm – February 27, 2025 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on difficult-to-treat cancers, has today resolved, by virtue of the authorisation by the Annual General Meeting held on 31 May 2024, to issue and immediately thereafter re-purchase a total of 10,572,577 class C shares

Stockholm – February 27, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2024

Stockholm – February 25, 2025 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus dexamethasone in patients with relapsed, refractory multiple myeloma (RRMM) has been published in the peer-reviewed journal European Journal of Haematology